January 2024 in “Wiadomości Lekarskie” Aortic aneurysm treatment has shifted to less invasive methods, improving safety and outcomes.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
January 2024 in “Wiadomości Lekarskie” Using Decamethoxine and Blastomunil together speeds up wound healing.
January 2024 in “Wiadomości Lekarskie” Pre-surgical embolization and a two-stage resection improve outcomes for rare sacral tumors.
January 2024 in “Wiadomości Lekarskie” A multidisciplinary approach is crucial for managing Silver-Russell syndrome effectively.
January 2024 in “Wiadomości Lekarskie” Countries should improve sex education, access to contraception, and legal abortion options.
January 2024 in “Wiadomości Lekarskie” Comprehensive treatment improved hearing in 89.7% of soldiers with blast-induced hearing loss.
January 2024 in “Wiadomości Lekarskie” Virtual surgical planning improves efficiency, coordination, and precision in complex surgeries.
11 citations
,
July 2014 in “Gene” The S250C variant in a gene may cause autoimmunity and immunodeficiency by impairing protein function.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
June 2024 in “International Journal of Nanomedicine” CRISPR/Cas9 has improved precision and control but still faces clinical challenges.
24 citations
,
July 2023 in “Journal of Functional Biomaterials” Bubble-based systems show promise for precise, targeted drug delivery and diagnosis, especially in cancer treatment.
May 2026 in “Mayo Clinic Proceedings” Early diagnosis and coordinated care are crucial for managing lupus effectively.
March 2026 in “Journal of Nanotheranostics” Nanotechnology improves CRISPR-Cas9 delivery for cancer treatment, but challenges remain.
June 2023 in “University of Thi-Qar Journal of Science” Retinoids effectively treat skin aging but have safety and stability issues.
5 citations
,
February 2024 in “Journal of Investigative Dermatology” Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
27 citations
,
September 2014 in “JAMA dermatology” Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.
12 citations
,
June 2020 in “Lupus” Early treatment with the right dose of stem cells can reduce lupus symptoms.
12 citations
,
April 2017 in “Experimental and Therapeutic Medicine” Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.
11 citations
,
February 1990 in “PubMed” Zinc may help treat alopecia areata by boosting certain immune cells.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.
October 2017 in “Journal of Investigative Dermatology” Pemphigus vulgaris involves specific immune cells and B cells that produce antibodies causing skin blisters.
May 2024 in “International journal of medicine and psychology.” Age-related immune changes significantly affect disease development in other systems.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
1 citations
,
May 2019 in “Cytotherapy” The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
January 2003 in “The Chinese Journal of Burns Wounds & Surface Ulcers” CK 19 expression is higher in more severe skin cancers.
159 citations
,
October 1986 in “The Histochemical Journal”
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.